Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 6/20 | 0.55 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL197253 | 0.91 | ELANE (0.49) | ELANEPARP1KMT2AALDH1A1MAPT | |
| SCHEMBL761836 | 0.79 | ELANE (0.53) | ELANEPARP1ALDH1A1MAPTKDM4E | |
| SCHEMBL7021949 | 0.77 | ELANE (0.49) | ELANEPARP1KMT2AALDH1A1MAPT | |
| SCHEMBL4591850 | 0.76 | MAPT (0.63) | ELANEKMT2AALDH1A1MAPTMEN1 | |
| SCHEMBL6558119 | 0.74 | ELANE (0.65) | ELANE | |
| SCHEMBL13075504 | 0.74 | ELANE (0.46) | ELANEPARP1KMT2AALDH1A1MAPT | |
| SCHEMBL3911656 | 0.73 | ALDH1A1 (0.50) | ELANEALDH1A1MAPTLMNAKDM4E | |
| SCHEMBL25530737 | 0.72 | ELANE (0.45) | ELANEPARP1KMT2AALDH1A1MAPT | |
| SCHEMBL3724946 | 0.72 | ELANE (0.48) | ELANEPARP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL8649103 | 0.72 | ELANE (0.51) | ELANEKMT2AALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070282101-A1 | Indazole compounds | CYP3A43, CYP3A7, UGT1A1 | ELANE 978/4885PARP1 1358/4885KMT2A 3965/4885 |
| US-20120053345-A1 | Indazole Compounds | CYP3A43, CYP3A7, UGT1A1 | ELANE 978/4885PARP1 1358/4885KMT2A 3965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.